

1 **SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in**
2 **Libya: cohort study**

3
4 Mohamed Hadi Mohamed Abdelhamid^{a,b}, Iman A. Almsellati^c, Badereddin B Annajar^d,
5 Alaa .H Abdelhamid^e, Hafsa .A Alemam^f, Mohammed Etikar^a.

6 ^a National Center of Disease Control (NCDC), Tripoli - Libya.

7 ^b Department of Cell Biology and Tissue Culture, Biotechnology Research Center
8 (BTRC), Tripoli - Libya.

9 ^c Primary Health Care, National Center of Disease Control (NCDC), Tripoli - Libya.

10 ^d Department of Public Health, Faculty of Medical Technology, University of Tripoli, Tripoli
11 13662, Libya.

12 ^e Department of Cardiology, Tripoli University Hospital, Tripoli, Libya.

13 ^f Department of Environment, Biotechnology Research Center (BTRC), Tripoli - Libya.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 * **Corresponding author:** Mohamed Hadi Mohamed Abdelhamid, National Center of
30 Disease Control (NCDC), Department of Cell Biology and Tissue Culture, Biotechnology
31 Research Center (BTRC), Tripoli - Libya; Email: Mohamed.abdelhamid@btc.org.ly ;
32 Moh9363@gmail.com Phone N: 00 218 916030276.

33

34 **Running title:** Breakthrough vaccine infection after one dose in Libya.

35

36

37 **Funding**

38 This research did not receive any specific grant from funding agencies in the public,
39 commercial, or not-for-profit sectors.

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56 **Abstract:**

57 SARS-CoV-2 infection is widely spread over people, from youth to the elderly.
58 Vaccination against SARS-CoV-2 is an important preventive measurement to help end
59 the SARS-CoV-2 pandemic. From 30 April to 15 July, we collected the number of people
60 infected with SARS-COV-2 and the mortality rate from daily reports issued by the National
61 Center for Disease Control of Libya (NCDC). Approximately 445000 doses have been
62 administered in Libya since 10 April, and 5 thousand doses are now being administered
63 during this period on a daily basis. To estimate the rate of breakthrough vaccine infection
64 of the SARS-COV-2 in Libya. We found that one dose of the three different types of
65 vaccines had decreased the virus transmission across people and mortality rate until 10
66 weeks after the first dose. This study highlights the dramatic success of the early months
67 of the nation's coronavirus vaccines rollout.

68 **Key Words:** SARS-COV-2; Breakthrough vaccines infection; One dose SARS-COV-2
69 vaccine; Libya

70

71

72

73

74

75

76

77 **Introduction:**

78 SARS-CoV-2 infection is widely spread over people, from youth to the elderly. Mass
79 vaccination operations to prevent coronavirus disease 2019 (Covid-19) are ensuing in
80 207 countries; 32% of the world population has received at least one dose of a SARS-
81 CoV-2 vaccine, and 24% is fully vaccinated [1]. Approximately 4,84 billion doses have
82 been administered worldwide, and 34,86 million are now administered daily [1,2].
83 Interestingly, SARS-CoV-2 several studies have found that most hospitalizations and
84 deaths due to SARS-CoV-2 infection were among immunocompromised individuals,
85 persons with co-morbidities, elderly and / or unvaccinated people [3–5].

86 Furthermore, previous studies showed that the vaccines reduce the risk of SARS-CoV-2
87 infection, especially illness severity, among partially vaccinated people [6–9] (Table 1).

88 Libya's National Center for Disease Control (NCDC) reported that the first case of
89 SARS-CoV-2 was identified in Libya on 24 Mars 2020 [10–12]. In addition, as reported
90 by the World Health Organization (WHO), many countries are not very well-prepared to
91 fight the pandemic such as (Libya, Iraq, and Yemen) these countries are more vulnerable
92 to the impact of this pandemic [13].

93 Nevertheless, In Libya, the national immunization program launched a long-delayed
94 SARS-CoV-2 vaccination program on 10 April 2021, through 400 immunization centers
95 distributor in all cities of the country [12].

96 Currently, most cases of SARS-CoV-2 effects people who have not been fully
97 vaccinated. Over the world, many hospitals have recorded cases of SARS-CoV-2
98 infection in patients after being fully vaccinated, this situation is called a vaccine

99 breakthrough cases [2,14]. Although SARS-CoV-2 vaccines right now appear to be very
100 effective against the disease severity and deaths, no vaccine is perfect [15].

101 Furthermore, two studies in Scotland and England confirm high protection rates (80%–
102 91%) after the first dose of Pfizer or Oxford/AstraZeneca vaccines [3,4]. Previous studies
103 have found that a single dose of the Sputnik V vaccine may be enough to elicit a strong
104 antibody response against SARS-CoV-2 [16,17]. However, In the United States, the U.S.
105 Center for Disease Control and Prevention (CDC) reported a total of 10,262 SARS-CoV-
106 2 vaccine breakthrough infections from 46 U.S. states and territories as of April 30,
107 2021[18]. A recent study reported that the effectiveness of the vaccines against infections
108 had decreased from 91.7% to 79.8% between 3 May and 25 July in New York [19].
109 Additionally, a study published by National Healthcare Safety Network (NHSN) found that
110 the two mRNA (nucleoside-modified) vaccines (Pfizer-BioNTech and Moderna) were
111 effective by 74.7% in nursing home residents between March and May, however, the
112 protection has declined to 53.1% between June and July[20].

113 Investigating the trend of SARS-CoV-2 infection severity, hospitalizations rate, and
114 deaths among persons who got the first dose of the SARS-CoV-2 vaccine are urgently
115 needed to support decision-making logistics such as cold chains, vaccination schedules,
116 and follow-up.

117

118

119

120

121 **Material and methods**

122 We collected SARS-CoV-2 infection and mortality rate data by the NCDC daily reports
123 from 30 April 2021 until 15 July 2021. The study includes all patients who were admitted
124 to hospitals with confirmed SARS-CoV-2 by repeat reverse-transcriptase–polymerase-
125 chain-reaction assays (RT-PCR). The data were collected from the medical record of the
126 patients by intensive care physicians and healthcare centers staff working in 34
127 healthcare centers and hospitals from different cities. Inclusion criteria were all vaccinated
128 and unvaccinated cases admitted to the healthcare centers during this period.
129 Concurrently, we tracked the number of people who received the first dose of the SARS-
130 CoV-2 vaccine since 10 April 2021.

131 **Ethics statement**

132 The study was approved by the Ethics Committee (National committee for Biosafety
133 and Bioethics at Biotechnology Research Center, Tripoli - Libya, N°: BTRC- 2021).

134

135 **First Dose of COVID-19 Vaccines:**

136 As the emergence of the new variant strains of SARS-CoV-2 B.1.617.2 (Delta) in the
137 world in December 2020, they have led to a rapid increase in the circulation of the virus
138 and a rising demands for vaccines.

139 UNICEF, through COVID-19 Vaccines Global Access (COVAX), supported the Libyan
140 government by delivering 57,600 doses at 8 April 2021[21]. Also, as an intranational gift
141 the Libya government received an around 200,000 doses of (Sputnik V) vaccines, and
142 150,000 doses of Sinovac vaccine on April 2021[12]. Thus, a countrywide mass
143 vaccination campaign with the use of three different authorized vaccines

144 (Oxford/AstraZeneca, Sinovac, Sputnik V) was conducted in Libya starting from 10 April,
145 2021[22]. Nearly 5000 doses were administered daily through 400 immunization centers
146 in all cities of the country. So far, about 445,000 people have received the first dose of
147 vaccines that provided by the national immunization program. Priority was given to
148 frontline healthcare and hospitals workers, adults over 60, and patients with chronic
149 underlying health conditions in all regions of the country.

150 Hence, 110,000 doses of Sinovac, 175,000 doses of Oxford/AstraZeneca, and 160,000
151 doses of Sputnik V were administered. The National Center for Disease Control (NCDC)
152 has recommended that the Oxford/AstraZeneca vaccine to be used for people aged over
153 55 years old. The other vaccines (Sinovac and Sputnik V) to be used for people who is
154 16 years old or more.

155 Moreover, due to delays in providing vaccines throughout COVAX and countries who
156 are producing the vaccines, the NCDC announced a deviation from the recommended
157 protocol for the SARS-CoV-2 vaccines, prolonging the interval between doses from 2 to
158 4 months. This procedure had two advantages: The first, a longer gap between doses
159 may improve the long-term immune response, as demonstrated by AstraZeneca's
160 vaccine[5]. Secondly, a larger number of elderly and people with chronic diseases will be
161 vaccinate.

162 **Hospital Admissions after one dose of vaccines**

163 As of 15 July 2021, approximately 445000 persons in Libya had been received the first
164 dose of the SARS-CoV-2 vaccines.

165 According to the NCDC data from 30 April 2021 (W1) to 15 July 2021 (W22), the total
166 number of patients who have a confirmed SARS-CoV-2 infection is 39996. 3179 out of
167 the total (7.9%) were admitted to healthcare centers, and among those 226 patients
168 (7.10%) died during this period.

169 At the same time, A total of 43 SARS-CoV-2 vaccine breakthrough infections (i.e. One
170 dose obtained from the vaccine) were reported from 18 healthcare centers and hospitals
171 as of 30 April 2021. Among these cases, 8 patients died. Patients in healthcare seem to
172 be moving towards an average age of around 55-87 years old (Table 2). Notably, 23
173 patients who were admitted to healthcare centers are vaccinated with the CoronaVac
174 (Sinovac) vaccine. 14 patients received the Oxford/AstraZeneca. While only two patients
175 had the Sputnik V vaccine.

176 Of 445000 people who had taken the first dose of the vaccines, the percentage of
177 patients who had been admitted to the healthcare centers, and died is very low (0.009,
178 0.001%) respectively.

179 Since July, the NCDC has reported initial evidence that people being infected with the
180 Delta variant. Where the numbers testing positive increased five-fold, from 1600 the
181 previous week to 15000 cases. It recorded its highest number of cases on 12 July (W20).
182 However, the number of patients' deaths remains lower compared to W11 (17-26 patients
183 per day) (Fig.1).

184 In this period (W20), with delays in travel restrictions, there has been a significant
185 increase in the number of people confirmed with SARS-CoV-2. Particularly in the western
186 cities such as (Zawiya, Tripoli, Shakshok, Zliten, and Misrata), due to proximity to the

187 Tunisian borders, which was recording the peak of infection rates in Africa and in the
188 world with Delta variant (Fig 2).

189 **Limitations of study**

190 The results in this study are subject to two limitations, the first one, that the number of
191 reported SARS-CoV-2 vaccine breakthrough cases is substantially lower than that of all
192 SARS-CoV-2 infections among one dose vaccinated persons. However, many people
193 with vaccine breakthrough infections, especially those who are asymptomatic or who
194 experience mild illness, might not seek testing. The second, SARS-CoV-2 sequence data
195 are available for only a small proportion of the reported cases.

196 **Conclusion**

197 In the present study, one dose of the three different types of vaccines had showed a
198 decreasing in infection and mortality rate. The results were very encouraging. However,
199 all these results were before the delta variant entered Libya. So as a recommendation,
200 the department of health and NCDC must focus and make all possible efforts to get as
201 many people vaccinated within a short period of time to prevent the development of new
202 virus variants.

203 **Acknowledgements**

204 The authors wish to thank all doctors in healthcare centers and hospitals who were
205 involved in this study, and Hamza El-thelb for editing the text.

206

207 **Conflicts of interest:** The authors have declared that no competing interests exist.

208

209 **Contributors:**

210 (I)Manuscript writing: All authors; (II) Final approval of manuscript: All authors.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227 **Reference**

- 228 1. Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie
229 Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald DB and MR.
230 Coronavirus Pandemic (COVID-19). OurWorldInData.org. 2021. Available:
231 <https://ourworldindata.org/covid-vaccinations#citation>
- 232 2. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.
233 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med*.
234 2021; 1–11. doi:10.1056/nejmoa2107715
- 235 3. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early
236 effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and
237 ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations
238 and mortality in older adults in England. *medRxiv*. 2021; 2021.03.01.21252652.
239 Available: <https://doi.org/10.1101/2021.03.01.21252652>
- 240 4. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim
241 findings from first-dose mass COVID-19 vaccination roll-out and COVID-19
242 hospital admissions in Scotland: a national prospective cohort study. *Lancet*.
243 2021;397: 1646–1657. doi:10.1016/S0140-6736(21)00677-2
- 244 5. Iacobucci G, Mahase E. Covid-19 vaccination: What’s the evidence for extending
245 the dosing interval? *BMJ*. 2021;372: n18. doi:10.1136/bmj.n18
- 246 6. Swan DA, Bracis C, Janes H, Moore M, Matrajt L, Reeves DB, et al. COVID-19
247 vaccines that reduce symptoms but do not block infection need higher coverage
248 and faster rollout to achieve population impact. *Sci Rep*. 2021;11: 1–9.

- 249 doi:10.1038/s41598-021-94719-y
- 250 7. Mallapaty BS. COVID VACCINES SLASH VIRAL SPREAD – BUT.
- 251 8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
252 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2021;384: 403–
253 416. doi:10.1056/nejmoa2035389
- 254 9. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of
255 Vaccination on Household Transmission of SARS-CoV-2 in England. *N Engl J*
256 *Med.* 2021;385: 759–760. doi:10.1056/nejmc2107717
- 257 10. Bredan A, Bakoush O. COVID-19 epidemic in Libya. *Libyan J Med.* 2021;16.
258 doi:10.1080/19932820.2021.1871798
- 259 11. Rayaes AA, Annajar BB, Dayhum AS, Eldaghayes IM. Why there were few cases
260 of coronavirus disease 2019 in Libya during the first two months of the pandemic?
261 *Int J One Heal.* 2020;6: 160–164. doi:10.14202/IJOH.2020.160-164
- 262 12. Mahmoud AS, Dayhum AS, Rayaes AA, Annajar BB, Eldaghayes IM. Exploiting
263 epidemiological data to understand the epidemiology and factors that influence
264 COVID-19 pandemic in Libya. *World J Virol.* 2021;10: 156–167.
265 doi:10.5501/wjv.v10.i4.156
- 266 13. Gasibat Q, Raba AA, Abobaker A. COVID-19 in Libya, fewer cases so far. Any
267 speculations? *Disaster Med Public Health Prep.* 2020; 2020–2021.
268 doi:10.1017/dmp.2020.177
- 269 14. Sankary KM, Sippel JL, Eberhart AC, Burns SP. Breakthrough cases of COVID-

- 270 19 in vaccinated United States Veterans with spinal cord injuries and disorders.
271 Spinal Cord. 2021; 1–2. doi:10.1038/s41393-021-00690-w
- 272 15. Dye C, Mills MC. COVID-19 vaccination passports. Science (80-). 2021;371.
273 doi:10.1126/science.abi5245
- 274 16. Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM,
275 Mazzitelli I, et al. Sputnik V vaccine elicits seroconversion and neutralizing
276 capacity to SARS-CoV-2 after a single dose. Cell Reports Med. 2021;2.
277 doi:10.1016/j.xcrm.2021.100359
- 278 17. Claro F, Silva D, Rodriguez M, Rangel R, de Waard JH. IgG Antibody response to
279 the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals might need
280 just one vaccine dose. Int J Infect Dis. 2021; 0–21. doi:10.1016/j.ijid.2021.07.070
- 281 18. CDC. COVID-19 Vaccine Breakthrough Infections Reported to CDC —. MMWR
282 Morb Mortal Wkly Rep. 2021;70: 792–793.
- 283 19. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D. New COVID-
284 19 Cases and Hospitalizations Among Adults , by Vaccination Status — New York
285 , May 3 – July 25 , 2021. 2021;70.
- 286 20. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H. Effectiveness of
287 Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection
288 Among Nursing Home Residents Before and During Widespread Circulation of
289 the SARS-CoV-2 B . 1 . 617 . 2 (Delta) Variant — National Healthcare Safety
290 Network , March. 2021;70: 1163–1166.

- 291 21. Situation H, No R, Status F, Appeal U. Libya Country Office. 2021; 1–10.
- 292 22. NDCD. weekly updet of COVID-19 Libya. In: NCDC Libya [Internet]. 2021 pp. 1–
- 293 5. Available: <https://ncdc.org.ly/Ar/>

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310 **Table and Figure legend**

311 **Table 1**

312 The efficacy of the vaccines against symptomatic, severe, and hospitalization SARS-
313 CoV-2 infection.

314 **Table 2**

315 Numbers of patients who were admitted to healthcare centers or hospitals after received
316 one dose of vaccine in Libya. N: Number DM: Diabetic HT: Hypertension
317 CoronaVac: Sinovac Astra: Oxford/AstraZeneca SputV: Sputnik v (-) = Data not
318 available.

319 **Figure 1**

320 Number of patients confirmed SARS-COV-2 Infection from February to 15 July in Libya.
321 Green ring: start to vaccines program Red ring: first cases with Delta variant.

322 **Figure 2**

323 The geographic distribution of SARS-COV-2 infection in Libya.

324

325

326

327

328

329

330 **Table 1. shows the efficacy of the vaccines against symptomatic, severe, and hospitalization**

331

SARS-CoV-2 infection.

Vaccines	<i>SARS-CoV-2 infection</i>	<i>vaccines against symptoms SARS-CoV-2 after receiving the first dose</i>	<i>Against hospitalization after receiving the first dose</i>
AstraZeneca	67 %	68.7%	76%
Sputnik-V	80%	81%	87%
CoronaVac	49.6%	70%	99.2%

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346


347

348
349

Table 2. Numbers of patients who were admitted to healthcare centers or hospitals after received one dose of vaccine in Libya

N	Healthcare center	N of patient (Type of vaccines)	N of died (Type of vaccine)
1	Derna	2 (CoronaVAC) 1 (Astra)	1 (Astra)
2	Marj	2 (CoronaVac)	0
3	Bayda	1 (CoronaVac)	0
4	Sabha	1 (Astra)	1 (Astra)
5	Tripoli1	1 (Astra) 1 (CoronaVac) 1 (Sput V)	1 (CoronaVac)
6	Tripoli 2	-	-
7	Zliten	3 (Astra)	0
8	Zawiya	-	-
9	Misrata	-	0
10	Zuwara	2 (CoronaVac) 1 (Astra)	1 (CoronaVac)
11	Tegy	1 (Astra)	0
12	Tobruq	2 (CoronaVac)	1 (Corona Vac)
13	Ghadames	2 (CoronaVac) 1 (Astra)	0
14	Benghazi	2 (Astra)	0
15	Shakshok	2 (CoronaVac)	1 (CoronaVac)
16	Msallata	3 (CoronaVac)	1 (CoronaVac)
17	Khoms1	1 (CoronaVac) 1 (Astra)	0
18	Khoms2	1 (Sput V) 3 (CoronaVac) 2 (Astra)	1 (CoronaVac)
		Total N of patient = 43	Total N of patient Died = 8

Fig 1. Number of patients who confirmed SARS-COV-2 Infection





Tunisia

Zuwarah

Tripoli

Az Zawiyah

Zintan

Misratah

Shakshok

Sirte

Benghazi

Bayda

Derna

Marj

Tobruq

Ajdabiya



Ghadames

Sabha

Libya